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Clinical manifestations of mastocytosis are mediated,
at least in part, by release of the mast cell mediators
histamine and prostaglandin D2. It has been previously
reported that in addition to prostaglandin D2, mast cells
produce other eicosanoids, including thromboxane.
Nonetheless, little information exists regarding the
formation of other prostanoids in vivo. The most
accurate method to examine the systemic production
of eicosanoids in vivo is the quantitation of urinary
metabolites. We previously developed a highly accurate
assay employing mass spectrometry to measure a
major urinary metabolite of thromboxane, 11-dehy-
dro-thromboxane B2, in humans. We utilized this assay
to quantitate thromboxane production in 17 patients
with histologically proven mastocytosis. We report that
thromboxane formation was significantly increased
(>2 SD above the mean) in at least one urine sample
from 65% of patients studied. Of these, 91% of patients
with documented systemic involvement had elevated
thromboxane generation. In addition, endogenous
Mastocytosis is a chronic disorder characterized byexcessive proliferation of mast cells in variousorgans (Roberts et al, 1998). It can be clinicallylimited to the skin (cutaneous mastocytosis) orinvolve multiple organs throughout the body
(systemic mastocytosis). Many patients with only cutaneous disease
on clinical examination, however, demonstrate increases in mast
cell numbers in the bone marrow (Guzzo et al, 1991). Patients
with systemic mastocytosis frequently experience episodes of mast
cell activation, characterized by intense flushing accompanied by
light headedness or syncope, gastrointestinal disturbances, and other
varied symptoms (Roberts et al, 1998). Although these episodes of
mast cell activation had been attributed to the release of increased
quantities of histamine from mast cells, treatment with antihistam-
ines was not found to prevent the episodes (Hirschowitz and
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formation of thromboxane was highly correlated with
the urinary excretion of the major urinary metabolite
of prostaglandin D2 (r J 0.98) and Nt-methylhistamine
(r J 0.91), suggesting that the cellular source of
increased thromboxane in vivo could be the mastocyte.
Enhanced thromboxane formation in patients with
this disorder is unlikely to be of platelet origin as other
markers of platelet activation, platelet factor 4 and b-
thromboglobulin, were not increased in three patients
with marked overproduction of thromboxane. Fur-
thermore, the recovery of 11-dehydro-thromboxane
B2 excretion in two patients after the administration
of aspirin occurred significantly more rapidly than the
recovery of platelet thromboxane generation. These
studies, therefore, report that thromboxane production
is significantly increased in the majority of patients
with mastocytosis that we examined and provide the
basis to elucidate the role of this eicosanoid in disorders
of mast cell activation. Key words: histamine/prosta-
glandin D2/thromboxane B2/urticaria pigmentosa. J Invest
Dermatol 113:93–97, 1999
Groarke, 1979; Roberts et al, 1980). Subsequently, it was found
that large quantities of prostaglandin (PG) D2 are released in
addition to histamine during episodes of mast cell activation in
patients with mastocytosis and PGD2 has been found to be an
important mediator of the humoral manifestations of the disease
(Roberts and Oates, 1991).
Although PGD2 has been reported to be overproduced during
mastocyte activation, little information exists regarding formation
of other eicosanoids in this disorder, particularly in vivo. It has been
previously reported that rat peritoneal mast cells in culture produce,
in addition to PGD2, large amounts of prostacyclin (PGI2), throm-
boxane (Tx) and PGF2α (Roberts et al, 1979). In contrast, in the
human mast cell leukemia line HMC-1, substantial amounts of
PGD2, TxB2, PGE2, and PGF2α are formed but very little PGI2
can be detected (Macchia et al, 1995). A single study in humans
reported that plasma levels of TxB2 are significantly increased in
humans with mastocytosis whereas quantities of 6-keto-PGF1α (the
stable hydrolysis product of PGI2) are decreased (Ouwendijk et al,
1983). Unfortunately, these latter findings are difficult to interpret
as plasma levels of both TxB2 and 6-keto-PGF1α are unreliable
indices of systemic Tx and PGI2 production, respectively, owing
to the fact that eicosanoids are readily generated by cellular elements
during blood sampling (Catella et al, 1986; Patrono, 1989). Thus,
whereas Tx is produced by mast cells ex vivo, whether Tx generation
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is increased in patients with mastocytosis in vivo has not been firmly
established.
The most accurate method to examine the systemic production
of eicosanoids in vivo is the quantitation of urinary metabolites
(Frolich et al, 1975; Catella et al, 1986). Previously, we developed
an assay to measure a major urinary metabolite of Tx, 11-dehydro-
TxB2, utilizing gas chromatography (GC)/negative ion chemical
ionization (NICI) mass spectrometry (MS) (Morrow and Minton,
1993). This method is a highly accurate tool to assess the endogenous
production of Tx in humans. We have now utilized this assay to
quantitate Tx production in 17 well characterized individuals with
mastocytosis. We report that Tx generation is significantly increased
in the majority of these patients. In addition, excretion of 11-
dehydro-TxB2 correlates closely with increased formation of the
two mast cell mediators, PGD2 and histamine.
MATERIALS AND METHODS
Materials [2H4]Nτ-methylhistamine was obtained from Merck, Sharp,
Dohme (MSD) isotopes (Montreal, Quebec, Canada). [2H4]11-dehydro-
TxB2, [
2H3]2,3-dinor-6-keto-PGF1α, and [
2H3]TxB2 were purchased from
Cayman Chemical (Ann Arbor MI). The major urinary metabolite of
PGD2 (PGD-M), 9α,11β-dihydroxy-15-oxo-2,3,18,19-tetranor-prost-5-
ene-1,20-dioic acid, was synthesized and converted to the [18O4]-labeled
internal standard as described (Morrow et al, 1991).
Measurement of 11-dehydro-TxB2, 2,3-dinor-6keto-PGF1a, PGD-
M, and Nτ-methylhistamine in urine 11-dehydro-TxB2, 2,3-dinor-
6-keto-PGF1α, PGD-M, and Nτ-methylhistamine were all measured in
urine by highly accurate, stable isotope GC/NICI MS assays (Morrow
et al, 1991, 1995; Morrow and Minton, 1993; Daniel et al, 1994). The
precision and accuracy of the assays are as follows: for 11-dehydro-TxB2
7% and 90%; for 2,3-dinor-6-keto-PGF1α 5% and 98%; for PGD-M 7%
and 96%; and for Nτ-methylhistamine 2% and 97%. The urinary creatinine
concentration was measured by the sodium picrate method with an
AutoAnalyzer II (Technicon, Tarrytown, NY). The levels of Nτ-methylhis-
tamine were expressed as pmol per µmol creatinine and levels of eicosanoid
metabolites as pmol per mmol creatinine. The normal range for each
substance was determined by measurements in 20 normal volunteers.
Quantitation of platelet factor 4 and b-thromboglobulin in plasma
and TxB2 in serum Levels of platelet factor 4 and β-thromboglobulin
in three patients with mastocytosis were quantitated in plasma utilizing
radioimmunoassays (Nichols et al, 1982). TxB2 was measured in serum ex
vivo after platelet activation by endogenous thrombin during whole blood
clotting at 37°C as described employing GC/NICI MS (FitzGerald
et al, 1983).
Clinical studies We evaluated 17 patients, 11 women and six men, who
had histologically documented urticaria pigmentosa skin lesions. The
clinical characteristics and urinary levels of Nτ-methylhistamine and PGD-
M in these individuals have been previously reported (Morrow et al, 1995).
The patients ranged in age from 20 to 65 y. All patients had scattered
urticaria pigmentosa lesions on at least 40% of their body surface. Fifteen
of the 17 individuals underwent bone marrow biopsies to assess whether
systemic involvement was present. Patients were admitted to the hospital,
and 24 h urine collections obtained for measurements of eicosanoids and
Nτ-methylhistamine after 48 h of a standardized low histidine, low histamine
diet to minimize dietary influences on levels of Nτ-methylhistamine. A
total of 46 urine samples were collected. All urine samples were stored
at –70°C until analyzed. None of the patients had taken nonsteroidal anti-
inflammatory drugs for at least 1 wk before the study.
In two patients with mastocytosis, an additional study was performed to
compare the suppression and recovery of endogenous Tx and PGD2
generation in response to aspirin treatment. Each individual was treated
with oral aspirin 160 mg twice daily for 4 d. Systemic Tx formation is
maximally inhibited by this dosage of aspirin (FitzGerald et al, 1983, 1987).
Urine and serum were collected before treatment and then daily on days
1–8 after therapy was stopped. Urine was quantitated for 11-dehydro-
TxB2 and PGD-M and TxB2 was measured in serum.
Statistical analyses Where appropriate, data was analyzed using linear
regression analysis and correlation employing Graphpad Instat Software
version 1.13 (Graphpad, San Diego, CA).
Table I. Clinical and laboratory data in 17 patients with
mastocytosis
Patient Age/sex Urticaria Symptoms Nodules in bone
pigmentosa marrow
A 44/F 1 – –
B 39/M 1 – –
C 46/F 1 1 (flushing, –
dizziness)
D 43/F 1 – –
E 22/M 1 – Not performed
F 20/F 1 – Not performed
G 38/F 1 – 1
H 30/M 1 – 1
I 32/M 1 – 1
J 40/M 1 1 (flushing, 1
dizziness)
K 23/F 1 – 1
L 30/M 1 1 (syncope) 1
M 27/F 1 1 (syncope) 1
N 34/F 1 – 1
O 33/F 1 – 1
p 45/F 1 1 (flushing) 1
Q 65/F 1 1 (syncope) 1
RESULTS
Clinical and laboratory data in patients with
mastocytosis Table I summarizes the clinical and laboratory
findings in 17 patients examined in this study. The patients can be
separated into three groups: four patients with cutaneous masto-
cytosis with no evidence of bone marrow involvement (patients
A–D); 11 patients with evidence of both cutaneous and marrow
involvement (patients G–Q); and two patients with cutaneous
disease who were not evaluated for the presence of bone marrow
involvement (patients E and F).
Urinary levels of 11-dehydro-TxB2 are increased in the
majority of patients with mastocytosis In 20 normal volun-
teers, urinary levels of 11-dehydro-TxB2 were 118 6 88 pmol per
mmol creatinine (mean 6 2 SD). Urinary 11-dehydro-TxB2 levels
measured in 17 patients with mastocytosis are shown in Fig 1.
The horizontal dashed line denotes the upper limits of normal
(2 SD above the mean) for urinary 11-dehydro-TxB2 levels. In
only six of 17 patients (35%) (patients A–E, H) was the urinary
excretion of 11-dehydro-TxB2 normal in all urine collections. In
contrast, in 10 of 17 patients (59%) (patients G, I–Q), 11-dehydro-
TxB2 were abnormally elevated in all urine collections whereas in
one patient (patient F), one of two urine collections had an
marginally elevated 11-dehydro-TxB2 level. In patient Q, increases
in Tx excretion were up to 48-fold above the upper limits of
normal. Therefore, the majority (65%) of patients in this study had
an elevated 11-dehydroTxB2 level in at least one 24 h urine
collection. Interestingly, of the individuals with increased Tx
excretion, all but one (91%) had evidence of systemic involvement
whereas no patients without evidence of systemic disease had
elevated levels of 11-dehydroTxB2. In comparison, we have previ-
ously reported that 94% of these patients had increased excretion
of PGD-M in at least one 24 h urine collection and 71% had at
least one urine sample with elevated Nτ-methylhistamine (Morrow
et al, 1995).
Correlation between the excretion of 11-dehydro-TxB2,
PGD-M, and Nτ-methylhistamine in patients with
mastocytosis Figure 2 compares the levels of 11-dehydro-TxB2
and PGD-M for the urine samples shown in Fig 1. The vertical
and horizontal dashed lines represent the upper limits of normal
values for 11-dehydro-TxB2 and PGD-M, respectively. As is
evident, increases in urinary excretion of 11-dehydro-TxB2 are
highly associated with and proportional to increases in levels of
PGD-M in the same samples. The correlation coefficient (r) for
the relationship is 0.98 and r2 5 0.95 (p , 0.0001).
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Figure 1. Urinary levels of 11-dehydro-TxB2 are increased in the
majority of 17 patients with mastocytosis. Each patient is denoted by
a letter which corresponds to the clinical and histologic data noted in
Table I. Each triangle represents a different 24 h urine collection for a
particular patient. The horizontal dashed line represents the upper limit
of normal (2 SD above the mean) for the urinary excretion of 11-
dehydro-TxB2.
Figure 2. Comparison of the urinary excretion of 11-dehydro-TxB2
to PGD-M in patients with mastocytosis. Each triangle represents a
different 24 h urine collection for a particular patient with mastocytosis.
The vertical and horizontal dashed lines represent the upper limits of
normal for 11-dehydro-TxB2 and PGD-M, respectively. Urinary levels of
both compounds were quantitated by GC/NICI MS assays. The correlation
coefficient for the relationship, r 5 0.98, r2 5 0.95, p , 0.0001.
Figure 3 compares the levels of 11-dehydro-TxB2 and N
τ-
methylhistamine for the urine samples shown in Fig 1. The vertical
and horizontal dashed lines represent the upper limits of normal
values for 11-dehydroTxB2 and N
τ-methylhistamine, respectively.
Again, increases in the urinary excretion of 11-dehydro-TxB2 are
highly associated with and proportional to increases in levels of
Nτ-methylhistamine in the same samples (r 5 0.91, r2 5 0.84,
p , 0.0001).
Figure 3. Comparison of the urinary excretion of 11-dehydro-TxB2
to Nτ-methylhistamine in patients with mastocytosis. Each triangle
represents a different 24 h urine collection for a particular patient with
mastocytosis. The vertical and horizontal dashed lines represent the upper
limits of normal for 11-dehydro-TxB2 and Nτ-methylhistamine,
respectively. Urinary levels of both compounds were quantitated by GC/
NICI MS assays. The correlation coefficient for the relationship, r 5 0.91,
r2 5 0.84, p , 0.0001.
Table II. Plasma platelet factor 4 and b-thromboglobulin
levels in three patients with mastocytosis in whom Tx
generation was markedly increased
Patient Platelet factor 4 β-thromboglobulin
(IU per ml)a (IU per ml)b
N 4 15
P 8 26
Q 6 16
aNormal plasma platelet factor 4 levels are 0–25 IU per ml.
bNormal β-thromboglobulin levels are 10–40 IU per ml.
Levels of platelet factor 4 and b-thromboglobulin in plasma
of patients with mastocytosis are not increased Although
Tx generation is significantly increased in the majority of patients
with mastocytosis, the cellular source of this eicosanoid is unknown.
It has been previously reported that rat peritoneal and human
leukemic mast cells produce prodigious amounts of TxB2 ex vivo
(Roberts et al, 1979; Macchia et al, 1995). The fact that increases
in the urinary excretion of 11-dehydro-TxB2 in patients with
mastocytosis correlate closely with both PGD-M and Nτ-methylhis-
tamine would support the contention that the source of excessive
Tx generation in patients with mastocytosis is the mastocyte. On
the other hand, the majority of endogenous Tx formed in normal
humans is of platelet origin (FitzGerald et al, 1983, 1987). Tx
formation is increased in vivo in disorders associated with platelet
activation including myocardial ischemia, vascular thromboses, and
pre-eclampsia, among others (FitzGerald et al, 1987). Similarly,
other markers of platelet activation are also increased in these
diseases, the most frequently measured indices being plasma platelet
factor 4 and β-thromboglobulin, which are proteins secreted from
platelet α-granules (Nichols et al, 1982; Kaplan, 1994). Therefore,
we reasoned that if excessive Tx production in patients with
mastocytosis is from platelets, then platelet factor 4 and β-thrombo-
globulin might also be increased. Table II shows plasma levels of
these two proteins measured in three of the 17 patients with
mastocytosis who were studied. All three patients had significantly
increased urinary 11-dehydro-TxB2 excretion. Levels of these
markers are normal, in contrast to Tx excretion, supporting the
concept that increased Tx generation in patients with mastocytosis
is likely not platelet-derived.
Effect of aspirin on suppression and recovery of Tx and
PGD2 formation in patients with mastocytosis We under-
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Figure 4. Effect of aspirin treatment on recovery of urinary 11-
dehydroTxB2 (n), urinary PGD-M (s), and serum TxB2 (u) in
two patients with mastocytosis. Each patient was treated with aspirin
160 mg orally twice a day for 4 d. Therapy was stopped on day 0 and
blood and urine collected for the subsequent 8 d. Data for each eicosanoid
are expressed percentage pre-aspirin treatment levels. In each patient,
pretreatment urinary excretion of both 11-dehydro-TxB2 and PGD-M
were markedly increased above the upper limits of normal.
took additional studies to determine the source of excessive Tx
production in patients with mastocytosis. Eicosanoid production
in human platelets is suppressed for a longer duration than that in
other cells by the administration of aspirin in vivo likely because
the platelet cannot synthesize new cyclooxygenase enzyme, unlike
other cellular elements (Campbell and Halushka, 1996). An accurate
index of platelet cyclooxygenase activity in vivo is the quantitation
of serum TxB2 generated in vitro by endogenous thrombin activation
during whole blood clotting (FitzGerald et al, 1983, 1987; Patrono,
1989). We reasoned, therefore, that if the majority of excessive Tx
production in patients with mastocytosis is derived from the platelet,
the administration of aspirin should affect the pattern of recovery
of both platelet TxB2 production and urinary 11-dehydroTxB2
excretion in a similar fashion. If aspirin affected the pattern of
recovery of serum TxB2 and 11-dehydro-TxB2 differently, how-
ever, this would imply that extraplatelet sources contribute substan-
tially to the excessive 11-dehydro-TxB2 excretion in patients with
mastocytosis (FitzGerald et al, 1983). We therefore quantitated
levels of serum TxB2, and urinary levels of 11-dehydro-TxB2 and
PGD-M, daily for 8 d in two individuals with mastocytosis who
had been administered aspirin (160 mg twice daily) for 4 d. Both
patients had markedly elevated levels of 11-dehydro-TxB2 at
baseline. The results are displayed in Fig 4(a, b). Administration
of aspirin suppressed urinary levels of 11-dehydroTxB2, PGD-M,
Table III. Levels of 2,3-dinor-6-keto-PGF1a in four
patients with mastocytosis
Patient 2,3-dinor-6-keto-PGF1α 11-dehydro-TxB2
(pmol per mmol Cr)a (pmol per mmol Cr)b
A 60 59
B 28 150
P 45 4280
Q 39 6720
aUrinary levels of 2,3-dinor-6-keto-PGF1α in normal humans are 45 6 17 pg per
mg Cr (mean 6 2 SD).
bUrinary levels of 11-dehydro-TxB2 in normal humans are 118 6 88 pmol per
mmol Cr.
and serum TxB2 . 95% in both patients. Following aspirin
treatment, a substantially different pattern of recovery of 11-
dehydro-TxB2 is apparent compared with recovery of serum TxB2.
Within 1.5 d, levels of 11-dehydro-TxB2 and PGD-M began to
increase and returned to pretreatment levels by days 3–4. On the
other hand, serum TxB2 levels remained completely suppressed
until after day 3 post-treatment and did not recover to near normal
levels until 6–8 d post-aspirin therapy.
Excretion of prostacyclin is not increased in patients with
mastocytosis It has been previously reported that in addition to
PGD2 and Tx, rat mast cells produce large amounts of PGI2
(Roberts et al, 1979). In contrast, however, one report has noted
that circulating levels of the PGI2 metabolite, 6-keto-PGF1α, are
reduced in patients with mastocytosis (Ouwendijk et al, 1983),
although quantitation of this compound is not an accurate index
of systemic prostacyclin generation in vivo (Catella et al, 1986).
Therefore, we quantitated levels of the major urinary metabolite
of PGI2, 2,3-dinor-6-keto-PGF1α (Daniel et al, 1994), in urine
samples from four of 17 patients with mastocytosis to assess whether
PGI2 was generated in increased quantities. The results are shown
in Table III. Two of the patients (A and B) had urinary levels of
11-dehydro-TxB2 that were not elevated and the other two (P and
Q) had markedly elevated excretion of the metabolite. As is evident,
in all patients, excretion of 2,3-dinor-6-keto-PGF1α was normal.
DISCUSSION
The results of this study provide evidence that systemic Tx
production is increased in the majority of humans with mastocytosis.
In the patient population that we examined, in which a diagnosis
of mastocytosis was carefully documented by both clinical and
laboratory examination, 65% of individuals studied had increased
excretion of 11-dehydro-TxB2 in at least one urine sample. In
addition, increased generation of Tx correlated in a highly significant
manner with enhanced formation of two mast cell mediators, PGD2
and histamine. Further, following the administration of aspirin to
two individuals with mastocytosis, the recovery of urinary 11-
dehydro-TxB2 excretion paralleled that of PGD-M. Taken together,
these data suggest that the cellular source of increased Tx formation
in patients with mastocytosis could be the mast cell. In this regard,
several investigators have reported that TxB2 is a major product of
animal or human mast cells stimulated ex vivo (Roberts et al, 1979;
Turner and Dollery, 1988; Undem et al, 1990; Macchia et al, 1995).
In addition, one study has noted an increase in levels of TxB2 in
blood from patients with mastocytosis (Ouwendijk et al, 1983).
Whereas these reports support the contention that the mast cell is
the source of increased Tx, other cell types produce this eicosanoid.
These include monocytes/macrophages and platelets (Patrono et al,
1985; Honda et al, 1990; Sanduja et al, 1991; Campbell and
Halushka, 1996). The vast majority of Tx production in normal
humans is believed to be of platelet origin (FitzGerald et al, 1983,
1987; Patrono, 1989). Thus, an important issue is whether platelets
contribute to the excessive Tx production in patients with masto-
cytosis. Our studies would suggest this is not the case as other
markers of platelet activation, platelet factor 4 and β-thromboglobu-
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lin, are not increased in mastocytosis patients with marked overprod-
uction of Tx. In addition, recovery of platelet Tx production after
suppression by aspirin is markedly delayed compared with that of
urinary 11-dehydro-TxB2 excretion in humans with mastocytosis.
Thus, whereas these observations do not rule out a significant
contribution by the platelet to Tx formation in these patients, our
findings suggest another cell type is more likely responsible.
In this study, 11 patients had evidence of systemic involvement
with mastocytosis. Interestingly, 10 of these 11 individuals (91%)
had increased urinary excretion of Tx whereas no patient without
evidence of systemic disease had an increased concentration of
urinary 11-dehydro-TxB2. These results suggest that elevated levels
of urinary 11-dehydro-TxB2 may be a predictor of systemic
involvement by mastocytosis in humans.
The significance of excessive Tx production in patients with
mastocytosis is unclear. TxA2 possesses a number of potent biologic
activities and is likely an important pathophysiologic mediator in
certain human diseases (Campbell and Halushka, 1996). Tx induces
bronchoconstriction and is believed to play a part in bronchial
hyperrepsonsiveness in asthma and acute allergic reactions (Fugi-
mura et al, 1991; Ohtsuka et al, 1996). Interestingly, whereas
dyspnea is unusual in settings of mast cell activation in patients
with mastocytosis, a fall in forced expiratory volume in 1 s can
usually be documented (Roberts et al, 1998). It is, therefore,
conceivable that overproduction of Tx might contribute to the
bronchoconstriction associated with mast cell activation.
TxA2 is also a potent vasoconstrictor in a number of vascular
beds (Campbell and Halushka, 1996). Although hypotension is
frequently associated with mast cell activation in patients with
mastocytosis, a subset of individuals become hypertensive (Roberts
et al, 1998). This has been previously attributed to alterations in
the metabolism of PGD2 with excessive formation of the reduced
metabolite 9α,11β-PGF2, which is a vasoconstrictor (Roberts et al,
1998). Alternatively, it is possible that in this subset of patients,
excessive Tx production could contribute to the hypertension. In
addition, TxA2 has been reported to be a potent mitogen and
induce cellular proliferation (Sachinidis et al, 1995; Palaka et al,
1997). Whether excessive production of Tx in mastocytosis contrib-
utes to mast cell proliferation is unknown.
In addition to quantitating Tx production, we also sought to
determine whether PGI2 formation was enhanced in patients with
mastocytosis. As noted, in four patients that we studied, we were
unable to document increases in this mediator, suggesting that
excessive prostacyclin production does not contribute to the
pathophysiology of mastocytosis.
In summary, we report that Tx production is significantly
increased in the majority of patients with mastocytosis that we
studied. The cellular source of this eicosanoid is unknown but it
does not appear to be of platelet origin. Experiments aimed at
definitively determining the cell responsible for excessive Tx
production in patients with mastocytosis will aid in future studies
designed to elucidate the role of this eicosanoid in the pathophysiol-
ogic sequelae of mast cell activation.
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